

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 49/00	A2	(11) International Publication Number: WO 99/08716 (43) International Publication Date: 25 February 1999 (25.02.99)
(21) International Application Number: PCT/GB98/02491 (22) International Filing Date: 19 August 1998 (19.08.98) (30) Priority Data: 9717589.7 19 August 1997 (19.08.97) GB (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/064,314 (CIP) Filed on 5 November 1997 (05.11.97) (71) Applicant (for GB only): MARSDEN, John, Christopher [GB/GB]; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB). (71) Applicant (for all designated States except US): NYCOMED IMAGING AS [NO/NO]; Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo (NO). (72) Inventor; and (75) Inventor/Applicant (for US only): OMTVEIT, Tore [NO/NO]; Otto Rugesvei 7, N-1343 Eiksmarka (NO).	(74) Agents: MARSDEN, John, Christopher et al.; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS		
(57) Abstract <p>The invention provides a process for the preparation of a fluorocarbon-containing lyophilised contrast agent which comprises lyophilising lyophilisable precursor material contained in one or more containers in a lyophilisation or like vacuum chamber, introducing said fluorinated gas into said chamber and effecting sealing closure of said container or containers, characterised in that, following closure of said container or containers, an overpressure of an atmospheric gas is applied to said chamber and said fluorocarbon gas is allowed to condense in a condensation vessel connected to said chamber.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

Improvements in or relating to contrast agents

5 This invention relates to the preparation of gas-containing contrast agents of use in diagnostic imaging.

10 It is well known that ultrasonic imaging comprises a potentially valuable diagnostic tool, for example in studies of the vascular system, particularly in
15 cardiography, and of tissue microvasculature. A variety of contrast agents has been proposed to enhance the acoustic images so obtained, including suspensions of solid particles, emulsified liquid droplets, gas bubbles and encapsulated gases or liquids. It is generally
20 accepted that low density contrast agents which are easily compressible are particularly efficient in terms of the acoustic backscatter they generate, and considerable interest has therefore been shown in the preparation of gas-containing and gas-generating systems.

25 Gas-containing contrast media are also known to be effective in magnetic resonance (MR) imaging, e.g. as susceptibility contrast agents which will act to reduce MR signal intensity. Oxygen-containing contrast media
30 also represent potentially useful paramagnetic MR contrast agents.

35 Furthermore, in the field of X-ray imaging it has been observed that gases such as carbon dioxide may be used as negative oral contrast agents or intravascular contrast agents.

 The use of radioactive gases, e.g. radioactive isotopes of inert gases such as xenon, has also been proposed in scintigraphy, for example for blood pool imaging.

 Initial studies involving free gas bubbles generated *in vivo* by intracardiac injection of physiologically acceptable substances have demonstrated

- 2 -

the potential efficiency of such bubbles as contrast agents in echography; such techniques are severely limited in practice, however, by the short lifetime of the free bubbles. Interest has accordingly been shown in methods of stabilising gas bubbles for echocardiography and other ultrasonic studies, for example using emulsifiers, oils, thickeners or sugars, or by entraining or encapsulating the gas or a precursor therefor in a variety of systems, e.g. as porous gas-containing microparticles or as encapsulated gas microbubbles.

There is a body of prior art regarding use of phospholipids as components of gas-containing ultrasound contrast agents. Thus, for example, the use as ultrasound contrast media of phospholipid liposomes in which a lipid bilayer surrounds a confined composition including a gas or gas precursor is disclosed in US-A-4900540. The encapsulated material is typically a gas precursor such as aqueous sodium bicarbonate, which is said to generate carbon dioxide following administration through exposure to body pH. The cores of the resulting liposomes will therefore tend to comprise liquid containing extremely small microbubbles of gas which will exhibit only limited echogenicity by virtue of their small size.

WO-A-9115244 discloses ultrasound contrast media comprising microbubbles of air or other gas formed in a suspension of liquid-filled liposomes, the liposomes apparently stabilising the microbubbles. Such systems are differentiated from those of the above-mentioned US-A-4900540 in which the air or other gas is inside the liposomes.

WO-A-9211873 describes aqueous preparations designed to absorb and stabilise microbubbles and thereby serve as ultrasound contrast agents, the compositions comprising polyoxyethylene/polyoxypropylene polymers and negatively charged phospholipids. The

- 3 -

weight ratio of polymer to phospholipid is typically about 3:1.

5 Ultrasound contrast agents comprising gas-filled liposomes, i.e. liposomes which are substantially devoid of liquid in the interior thereof, and their preparation by a vacuum drying gas instillation method are described in WO-A-9222247. The preparation of such gas-filled liposomes by a gel state shaking gas instillation method is described in WO-A-9428780. A report on gas-filled
10 lipid bilayers composed of dipalmitoylphosphatidylcholine as ultrasound contrast agents is presented by Unger et al. in Investigative Radiology 29, Supplement 2, S134-S136 (1994).

15 WO-A-9409829 discloses injectable suspensions of gas microbubbles in an aqueous carrier liquid comprising at least one phospholipid stabiliser, the concentration of phospholipids in the carrier being less than 0.01% w/w but equal to or above the amount at which phospholipid molecules are present solely at the gas
20 microbubble-liquid interface. The amount of phospholipid may therefore be as low as that necessary for formation of a single monolayer of surfactant around the gas microbubbles, the resulting film-like structure stabilising the bubbles against collapse or coalescence.
25 Microbubbles with a liposome-like surfactant bilayer are said not to be obtained when such low phospholipid concentrations are used.

30 A further body of prior art concerns selection of gases for gas microbubble-containing ultrasound contrast media in order to enhance properties such as their stability and duration of echogenic effect. Thus, for example, WO-A-9305819 proposes use of free microbubbles of gases having a coefficient Q greater than 5 where

$$Q = 4.0 \times 10^{-7} \times \rho / C_s D$$

35 (where ρ is the density of the gas in kg.m^{-3} , C_s is the water solubility of the gas in moles.l^{-1} and D is the diffusivity of the gas in solution in $\text{cm}^3.\text{sec}^{-1}$). An

- 4 -

extensive list of gases said to fulfill this requirement is presented.

EP-A-0554213 suggests that one may impart resistance against collapse under pressure to gas-filled microvesicles by introduction thereto of at least one gas whose solubility in water, expressed in litres of gas/litres of water under standard conditions, divided by the square root of its molecular weight does not exceed 0.003. Preferred gases are said to include sulphur hexafluoride, selenium hexafluoride and various Freons®. Such gases may, *inter alia*, be used in phospholipid-containing compositions of the type described in the above-mentioned WO-A-9215244.

Schneider et al. in *Investigative Radiology* 30(8), pp.451-457 (1995) describe a new ultrasonographic contrast agent based on sulphur hexafluoride-filled microbubbles apparently stabilised by a combination of polyethyleneglycol 4000 and a mixture of the phospholipids distearoylphosphatidylcholine and dipalmitoylphosphatidylglycerol. The use of sulphur hexafluoride rather than air is said to provide improved resistance to pressure increases such as occur in the left heart during systole.

WO-A-9503835 proposes use of microbubbles containing a gas mixture the composition of which is based on considerations of gas partial pressures both inside and outside the microbubbles, so as to take account of osmotic effects on microbubble size. Representative mixtures comprise a gas having a low vapour pressure and limited solubility in blood or serum (e.g. a fluorocarbon) in combination with another gas which is more rapidly exchanged with gases present in normal blood or serum (e.g. nitrogen, oxygen, carbon dioxide or mixtures thereof).

WO-A-9516467 suggests use of ultrasound contrast media containing a mixture of gases A and B, where gas B is present in an amount of 0.5 - 41% v/v, has a

- 5 -

molecular weight greater than 80 daltons and has aqueous solubility below 0.0283 ml/ml water under standard conditions, the balance of the mixture being gas A. Representative gases A include air, oxygen, nitrogen, carbon dioxide and mixtures thereof. Representative gases B include fluorine-containing gases such as sulphur hexafluoride and various perfluorinated hydrocarbons. Preferred stabilisers in such contrast media include phospholipids.

Phospholipids said to be useful in prior art contrast agents include lecithins (i.e. phosphatidylcholines), for example natural lecithins such as egg yolk lecithin or soya bean lecithin and synthetic or semisynthetic lecithins such as dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine or distearoylphosphatidylcholine; phosphatidic acids; phosphatidylethanolamines; phosphatidylserines; phosphatidylglycerols; phosphatidylinositols; cardiolipins; sphingomyelins; mixtures of any of the foregoing and mixtures with other lipids such as cholesterol. Lecithin derivatives generally appear to be the most commonly used phospholipids, possibly by virtue of their ready availability from natural sources. The use of additives such as cholesterol in amounts of up to 50% w/w is disclosed in WO-A-9115244 and WO-A-9409829, whilst the incorporation of at least a small amount (e.g. ca. 1 mole %) of negatively charged lipid (e.g. phosphatidylserine or a fatty acid) to enhance stability is suggested in WO-A-9222247. A preferred phospholipid composition according to WO-A-9428780 comprises dipalmitoylphosphatidylcholine, polyethylene-glycol 5000-substituted dipalmitoylphosphatidylethanolamine and dipalmitoylphosphatidic acid in molar proportions of about 87:8:5. Typical mixed phospholipid compositions according to WO-A-9409829 and WO-A-9516467 comprise diarachidoylphosphatidylcholine and dipalmitoylphosphatidic acid in weight proportions of

- 6 -

about 100:4, although the latter specification also exemplifies use of equal amounts by weight of distearoylphosphatidylcholine and dipalmitoylphosphatidylglycerol.

5 It will be apparent from the foregoing that in existing phospholipid-containing microbubble suspensions proposed for use as contrast media, at least 50% of the phospholipid content comprises neutral phospholipids such as lecithins. Most commonly only a minor
10 proportion, e.g. ca. 5%, of charged phospholipids is present.

 It is reported in WO97/29783 that the use of predominantly charged phospholipids as essentially the sole amphiphilic component of microbubble-containing
15 contrast agents may convey valuable and unexpected benefits in terms of parameters such as product stability and acoustic properties. Without wishing to be bound by theoretical considerations it is believed that electrostatic repulsion between charged
20 phospholipid membranes encourages the formation of stable and stabilising monolayers at microbubble-carrier liquid interfaces and that the flexibility and deformability of such thin membranes enhances the echogenicity of such products relative to gas-filled
25 liposomes comprising one or more lipid bilayers.

 It is also suggested that the use of charged phospholipids may enable the provision of microbubble contrast agents with advantageous properties regarding, for example, stability, dispersibility and resistance to
30 coalescence without recourse to additives such as further surfactants and/or viscosity enhancers, thereby ensuring that the number of components administered to the body of a subject upon injection of the contrast agents is kept to a minimum. Thus, for example, the
35 charged surfaces of the microbubbles may minimise or prevent their aggregation as a result of electrostatic repulsion.

- 7 -

According to one embodiment of W097/29783 there is provided a contrast agent for use in diagnostic studies comprising a suspension in an injectable aqueous carrier liquid of gas microbubbles stabilised by phospholipid-containing amphiphilic material characterised in that
5 said amphiphilic material consists essentially of phospholipid predominantly comprising molecules with net charges.

Desirably at least 75%, preferably substantially
10 all of the phospholipid material in such contrast agents consists of molecules bearing a net overall charge under conditions of preparation and/or use, which charge may be positive or, more preferably, negative.
Representative positively charged phospholipids include
15 esters of phosphatidic acids such as dipalmitoylphosphatidic acid or distearoyl-phosphatidic acid with aminoalcohols such as hydroxyethylenediamine. Examples of negatively charged phospholipids include naturally occurring (e.g. soya bean or egg yolk
20 derived), semisynthetic (e.g. partially or fully hydrogenated) and synthetic phosphatidylserines, phosphatidylglycerols, phosphatidylinositols, phosphatidic acids and cardiolipins. The fatty acyl groups of such phospholipids will typically each contain
25 about 14-22 carbon atoms, for example as in palmitoyl and stearyl groups. Lyso forms of such charged phospholipids are also useful, the term "lyso" denoting phospholipids containing only one fatty acyl group, this preferably being ester-linked to the 1-position carbon
30 atom of the glyceryl moiety. Such lyso forms of charged phospholipids may advantageously be used in admixture with charged phospholipids containing two fatty acyl groups.

Phosphatidylserines represent particularly
35 preferred phospholipids of use in such contrast agents and preferably constitute a substantial part, e.g. at least 80% of the initial phospholipid content thereof,

- 8 -

for example 85-92%, although this may subsequently be reduced somewhat, e.g. to ca. 70%, in subsequent processing such as heat sterilisation. It will be appreciated that such processing may lead to formation of non-phospholipid degradation products such as free fatty acids, e.g. at levels of up to 10%; references herein to amphiphilic material consisting essentially of phospholipid are to be construed as embracing phospholipids containing such free fatty acids. While we do not wish to be bound by theoretical considerations, it may be that ionic bridging between the carboxyl and amino groups of adjacent serine moieties contributes to the stability of phosphatidylserine-containing systems, for example as evidenced by their good pressure stability. Preferred phosphatidylserines include saturated (e.g. hydrogenated or synthetic) natural phosphatidylserine and synthetic or semi-synthetic dialkanoylphosphatidylserines such as distearoylphosphatidylserine, dipalmitoylphosphatidylserine and diarachidoylphosphatidylserine.

An important advantage of the use of such phosphatidylserine-based contrast agents is that the body recognises aged red blood cells and platelets by high concentrations of phosphatidylserine on their surface and so may eliminate such contrast agents from the blood stream in a manner similar to the elimination of red blood cells. Furthermore, since the surface of such contrast agents may be registered as endogenous by the body, they may avoid induction of adverse systemic side effects such as haemodynamic effects and other anaphylactic reactions which may accompany administration of some liposome preparations (see e.g. WO-A-9512386). In support of this, no acute toxic effects such as changes in blood pressure or heart rate have been observed in animal tests on dogs injected with intravenous boluses of contrast agents according to WO97/29783 at doses of up to ten times a normal imaging

- 9 -

dose.

Any biocompatible gas may be employed in such contrast agents, it being appreciated that the term "gas" as used herein includes any substances (including mixtures) substantially or completely in gaseous (including vapour) form at the normal human body temperature of 37°C. The gas may thus, for example, comprise air; nitrogen; oxygen; carbon dioxide; hydrogen; nitrous oxide; an inert gas such as helium, argon, xenon or krypton; a sulphur fluoride such as sulphur hexafluoride, disulphur decafluoride or trifluoromethylsulphur pentafluoride; selenium hexafluoride; an optionally halogenated silane such as tetramethylsilane; a low molecular weight hydrocarbon (e.g. containing up to 7 carbon atoms), for example an alkane such as methane, ethane, a propane, a butane or a pentane, a cycloalkane such as cyclobutane or cyclopentane, an alkene such as propene or a butene, or an alkyne such as acetylene; an ether; a ketone; an ester; a halogenated low molecular weight hydrocarbon (e.g. containing up to 7 carbon atoms); or a mixture of any of the foregoing. At least some of the halogen atoms in halogenated gases advantageously are fluorine atoms. Thus biocompatible halogenated hydrocarbon gases may, for example, be selected from bromochlorodifluoromethane, chlorodifluoromethane, dichlorodifluoromethane, bromotrifluoromethane, chlorotrifluoromethane, chloropentafluoroethane, dichlorotetrafluoroethane and perfluorocarbons, e.g. perfluoroalkanes such as perfluoromethane, perfluoroethane, perfluoropropanes, perfluorobutanes (e.g. perfluoro-n-butane, optionally in admixture with other isomers such as perfluoroisobutane), perfluoropentanes, perfluorohexanes and perfluoroheptanes; perfluoroalkenes such as perfluoropropene, perfluorobutenes (e.g. perfluorobut-2-ene) and perfluorobutadiene; perfluoroalkynes such as

- 10 -

perfluorobut-2-yne; and perfluorocycloalkanes such as perfluorocyclobutane, perfluoromethylcyclobutane, perfluorodimethylcyclobutanes, perfluorotrimethylcyclobutanes, perfluorocyclopentane, perfluoromethylcyclopentane, perfluorodimethylcyclopentanes, perfluorocyclohexane, perfluoromethylcyclohexane and perfluorocycloheptane. Other halogenated gases include fluorinated, e.g. perfluorinated, ketones such as perfluoroacetone and fluorinated, e.g. perfluorinated, ethers such as perfluorodiethyl ether.

It may be advantageous to employ fluorinated gases such as sulphur fluorides or fluorocarbons (e.g. perfluorocarbons) which are known to form particularly stable microbubble suspensions (see, for example, the article by Schneider et al. referred to above). Gas mixtures based on considerations of partial pressures both inside and outside the microbubbles and consequent osmotic effects on microbubble size, e.g. as described in WO-A-9503835, may if desired be employed, for example a mixture of a relatively blood-soluble gas such as nitrogen or air and a relatively blood-insoluble gas such as a perfluorocarbon.

It has, however, been found that contrast agents according to WO97/29783, for example comprising microbubbles of a perfluoroalkane such as perfluorobutane stabilised by phosphatidylserine, are surprisingly stable in size following intravenous administration to a subject, and do not exhibit the previously described tendency of microbubbles of such gases to grow uncontrollably as a result of inward diffusion of blood gases such as oxygen, nitrogen and carbon dioxide, instead rapidly reaching a maximum size beyond which further growth is not observed. This avoidance of unlimited size increases which could lead to undesirable and potentially highly dangerous blocking of blood vessel capillaries is a major advantage of

- 11 -

such contrast agents.

Contrast agents comprising perfluoroalkanes such as perfluorobutane have also been found to exhibit surprisingly high stability under pressures similar to those typically encountered *in vivo*, for example showing substantially complete (e.g. at least 90%) recovery to normal size distribution and echogenic properties after exposure to overpressures (e.g. of air) of up to 300mm Hg for 90 seconds.

The contrast agents of WO97/29783 may be used in a variety of diagnostic imaging techniques, including scintigraphy, light imaging, ultrasound, MR and X-ray (including soft X-ray) imaging. Their use in diagnostic ultrasound imaging and in MR imaging, e.g. as susceptibility contrast agents, constitute preferred features of the invention. A variety of imaging techniques may be employed in ultrasound applications, for example including fundamental and harmonic B-mode imaging and fundamental and harmonic Doppler imaging; if desired three-dimensional imaging techniques may be used. The contrast agent may also be used in ultrasound imaging methods based on correlation techniques, for example as described in US-A-5601085 and WO97/12551.

In vivo ultrasound tests in dogs have shown that such contrast agents may produce an increase in backscattered signal intensity from the myocardium of 15-25 dB following intravenous injection of doses as low as 1-20 nl microbubbles/kg body weight. Signals may be observed at even lower doses using more sensitive techniques such as colour Doppler or Doppler-derived techniques, e.g. amplitude based Doppler or non-linear techniques such as are described by Tucker et al. in Lancet (1968) p. 1253, by Miller in Ultrasonics (1981) pp. 217-224, and by Newhouse et al. in J. Acoust. Soc. Am. 75, pp. 1473-1477 (1984). At these low doses attenuation in blood-filled compartments such as the

- 12 -

heart chambers has been found to be sufficiently low to permit visualisation of regions of interest in the myocardial vasculature. Tests have also shown such intravenously injected contrast agents to be distributed throughout the whole blood pool, thereby enhancing the echogenicity of all vascularised tissues, and to be recirculated. They have also been found useful as general Doppler signal enhancement aids, and may additionally be useful in ultrasound computed tomography and in physiologically triggered or intermittent imaging.

For ultrasound applications such as echocardiography, in order to permit free passage through the pulmonary system and to achieve resonance with the preferred imaging frequencies of about 0.1-15 MHz, it may be convenient to employ microbubbles having an average size of 0.1-10 μm , e.g. 1-7 μm . Contrast agents according to WO97/29783 may be produced with a very narrow size distribution for the microbubble dispersion within the range preferred for echocardiography, thereby greatly enhancing their echogenicity as well as their safety *in vivo*, and rendering the contrast agents of particular advantage in applications such as blood pressure measurements, blood flow tracing and ultrasound tomography. Thus, for example, products in which over 90% (e.g. at least 95%, preferably at least 98%) of the microbubbles have diameters in the range 1-7 μm and less than 5% (e.g. not more than 3%, preferably not more than 2%) of the microbubbles have diameters above 7 μm may readily be prepared.

In ultrasound applications such contrast agents may, for example, be administered in doses such that the amount of phospholipid injected is in the range 0.1-10 $\mu\text{g/kg}$ body weight, e.g. 1-5 $\mu\text{g/kg}$ in the case of fundamental B-mode imaging. It will be appreciated that the use of such low levels of phospholipid is of

- 13 -

substantial advantage in minimising possible toxic side effects. Furthermore, the low levels of phospholipids present in effective doses may permit dosage increases to prolong observation times without adverse effects.

5 The overall concentration of phospholipid in injectable forms of such contrast agents may conveniently be in the range 0.01-2%w/w, for example 0.2-0.8%w/w, advantageously about 0.5%w/w.

10 In general it is unnecessary to incorporate additives such as emulsifying agents and/or viscosity enhancers which are commonly employed in many existing contrast agent formulations into contrast agents according to WO97/29783; this is of advantage in keeping to a minimum the number of components administered to
15 the body of a subject and ensuring that the viscosity of the contrast agents is as low as possible. Since preparation of the contrast agents typically involves a freeze drying step as discussed in further detail hereinafter it may, however, be advantageous to include
20 one or more agents with cryoprotective and/or lyoprotective effect and/or one or more bulking agents, for example an alcohol, e.g. an aliphatic alcohol such as t-butanol; a polyol such as glycerol; an aminoacid such as glycine; a carbohydrate, e.g. a sugar such as
25 sucrose, mannitol, trehalose, glucose, lactose or a cyclodextrin, or a polysaccharide such as dextran; or a polyglycol such as polyethylene glycol. A substantial list of agents with cryoprotective and/or lyoprotective effects is given in Acta Pharm. Technol. 34(3), pp. 129-
30 139 (1988), the contents of which are incorporated herein by reference. The use of physiologically well-tolerated sugars such as sucrose, e.g. in an amount such as to render the product isotonic or somewhat hypertonic, is preferred.

35 Prior art microbubble-containing contrast agents, for example as described in WO-A-9409829, are typically prepared by contacting powdered surfactant, e.g. freeze-

- 14 -

dried preformed liposomes or freeze-dried or spray-dried phospholipid solutions, with air or other gas and then with aqueous carrier, agitating to generate a microbubble suspension which must then be administered shortly after its preparation. Such processes, however, suffer the disadvantages that substantial agitational energy must be imparted to generate the required dispersion and that the size and size distribution of the microbubbles are dependent on the amount of energy applied and so cannot in practice be controlled.

Contrast agents according to WO97/29783 may advantageously be prepared by generating a gas microbubble dispersion in an appropriate phospholipid-containing aqueous medium, which may if desired previously have been autoclaved or otherwise sterilised, and thereafter subjecting the dispersion to lyophilisation to yield a dried reconstitutable product. Where the dried product contains one or more cryoprotective and/or lyoprotective agents it may, for example, comprise a microbubble-releasing cryoprotectant and/or lyoprotectant (e.g. carbohydrate) matrix containing gas-filled substantially spherical cavities or vacuoles surrounded by one or more layers of the amphiphilic material.

Dried products so prepared are especially readily reconstitutable in aqueous media such as water, an aqueous solution such as saline (which may advantageously be balanced so that the final product for injection is not hypotonic), or an aqueous solution of one or more tonicity-adjusting substances such as salts (e.g. of plasma cations with physiologically tolerable counterions), or sugars, sugar alcohols, glycols and other non-ionic polyol materials (e.g. glucose, sucrose, sorbitol, mannitol, glycerol, polyethylene glycols, propylene glycols and the like) requiring only minimal agitation such as may, for example, be provided by gentle hand-shaking. The size of the microbubbles so

- 15 -

generated is consistently reproducible and in practice is independent of the amount of agitational energy applied, being determined by the size of the microbubbles formed in the initial microbubble dispersion, this size parameter surprisingly being substantially maintained in the lyophilised and reconstituted product. Thus, since the size of the microbubbles in the initial dispersion may readily be controlled by process parameters such as the method, speed and duration of agitation, the final microbubble size may readily be controlled.

Dried products so prepared have also proved to be storage stable for several months under ambient conditions. The microbubble dispersions generated upon reconstitution in water or an aqueous solution may be stable for at least 12 hours, permitting considerable flexibility as to when the dried product is reconstituted prior to injection.

The above-described process is generally applicable to the preparation of contrast agents comprising suspensions in an injectable aqueous carrier liquid of gas microbubbles stabilised by membrane-forming lipids, including both neutral and charged lipids (e.g. phospholipids) as well as mixtures thereof, and may be summarised as comprising the steps:

- i) generating a dispersion of gas microbubbles in an aqueous medium containing a membrane-forming lipid;
- ii) lyophilising the thus-obtained lipid-stabilised gas dispersion to yield a dried lipid-containing product; and
- iii) reconstituting the said dried product in an injectable aqueous carrier liquid.

Step (i) may, for example, be effected by subjecting the lipid-containing aqueous medium to any appropriate emulsion-generating technique, for example sonication, shaking, high pressure homogenisation, high speed stirring or high shear mixing, e.g. using a rotor-

- 16 -

stator homogeniser, in the presence of the selected gas. The aqueous medium may, if desired, contain additives which serve as viscosity enhancers and/or as solubility aids for the lipid, such as alcohols or polyols, e.g. glycerol and/or propylene glycol.

The gas employed in the emulsification step need not be that desired in the final product. Thus most of this gas content may be removed during the subsequent lyophilisation step and residual gas may be removed by evacuation of the dried product, to which an atmosphere of the desired end product gas may then be applied. The emulsification gas may therefore be selected purely to optimise the emulsification process parameters, without regard to end product considerations. Emulsification in the presence of a sulphur fluoride such as sulphur hexafluoride or a fluorinated hydrocarbon gas such as a perfluoroalkane or perfluorocycloalkane, preferably containing 4 or 5 carbon atoms, may be particularly advantageous in terms of ultimately yielding end products with consistent and narrowly distributed microbubble sizes.

Dispersions produced according to step (i) may advantageously be subjected to one or more washing steps prior to contrast agent use or to lyophilisation step (ii), in order to separate and remove additives such as viscosity enhancers and solubility aids, as well as unwanted material such as non-gas-containing colloidal particles and undersized and/or oversized microbubbles; the washed microbubble dispersions so obtained constitute a feature of the invention. Such washing may be effected in *per se* known manner, the microbubbles being separated using techniques such as flotation or centrifugation. The ability to remove additives in this way and also to obtain microbubble dispersions with a particularly narrow size distribution represent important advantages of the process, especially since, as noted above, the resulting size distribution is

- 17 -

substantially retained after lyophilisation and reconstitution. In order to obtain a homogeneous product in step (ii) it is preferred that the dispersion from step (i) is frozen as quickly as possible, for example using a cooling medium such as liquid nitrogen. Accordingly it is particularly preferred to use a process comprising gas dispersion, washing/separation, rapid freezing, lyophilisation and reconstitution steps.

Size-fractionated microbubble dispersions may be prepared wherein at least 90% of the microbubbles have sizes within a 2 μm range, the microbubbles preferably having a volume mean diameter within the range 2-5 μm .

Where one or more cryoprotective and/or lyoprotective agents are employed these may advantageously be added after the washing steps, prior to lyophilisation.

Lyophilisation of the gas dispersion may, for example, be effected by initially freezing it and thereafter lyophilising the frozen gas dispersion, for example in *per se* generally known manner. The microbubbles may preferably be size fractionated prior to freezing, the released microbubbles preferably having a volume mean diameter within the range 2-5 μm . Such products may be stored frozen and thawed when desired, e.g. by simple warming and/or by addition of a carrier liquid, to regenerate microbubble dispersions useful as contrast agents.

Since the dried product will normally be reconstituted in accordance with step (iii) above prior to administration, the gas dispersion may advantageously be filled into sealable vials prior to lyophilisation so as to give vials each containing an appropriate amount, e.g. a single dosage unit, of lyophilised dried product for reconstitution into an injectable form. By lyophilising the gas dispersion in individual vials rather than in bulk, handling of the delicate honeycomb-like structure of the lyophilised product and the risk

- 18 -

of at least partially degrading this structure are avoided. Following lyophilisation and any optional further evacuation of gas and introduction into the headspace of gas desired to be present as microbubbles in the ultimately formulated contrast agent, the vials may be sealed with an appropriate closure. It will be appreciated that the ability to select the end product gas content, coupled with the ability independently to control the end product microbubble size by selection of appropriate process parameters during the initial dispersion step and any ensuing washing/separation step, enable the independent selection of microbubble size and gas content, thereby permitting the products to be matched to particular applications.

In general the frozen gas dispersion or the dried product from step (ii), e.g. after any necessary and/or desired supplementation or exchange of gas content, may be reconstituted by addition of an appropriate sterile aqueous injectable carrier liquid such as sterile pyrogen-free water for injection, an aqueous solution such as saline (which may advantageously be balanced so that the final product for injection is not hypotonic), or an aqueous solution of one or more tonicity-adjusting substances (e.g. as hereinbefore described). Where the dried product is contained in a vial this is conveniently sealed with a septum through which the carrier liquid may be injected using an optionally prefilled syringe; alternatively the dried product and carrier liquid may be supplied together in a dual chamber device such as a dual chamber syringe. It may be advantageous to mix or gently shake the product following reconstitution. However, as noted above, in the stabilised contrast agents according to the invention the size of the gas microbubbles may be substantially independent of the amount of agitational energy applied to the reconstituted dried product. Accordingly no more than gentle hand-shaking may be

- 19 -

required to give reproducible products with consistent microbubble size.

5 In cases where a desired gas such as a fluorocarbon is to be applied to lyophilised products prepared as above, e.g. contained in individual vials, this may be effected by feeding the desired gas into the lyophilisation chamber or an associated vacuum chamber containing the vials of lyophilised product, whereafter the vials may be stoppered or otherwise sealed and
10 removed from the chamber. By virtue of the cost and potential greenhouse effects of fluorocarbon gases and other gases as listed above it is undesirable for both economic and environmental reasons simply to allow residual fluorocarbon gas to escape into the atmosphere
15 when removing the sealed vials from the chamber. One embodiment of the present invention is based on the finding that such residual gases may advantageously be isolated in a separate condensation vessel prior to opening of the chamber to remove the vials.

20 Thus according to one aspect of the present invention there is provided a process for the preparation of a fluorocarbon-containing lyophilised contrast agent which comprises lyophilising lyophilisable precursor material contained in one or
25 more containers such as vials in a lyophilisation or like vacuum chamber, introducing said fluorinated gas into said chamber and effecting sealing closure of said container or containers, characterised in that, following closure of said container or containers, an
30 overpressure of an atmospheric gas is applied to said chamber and said fluorocarbon gas is allowed to condense in a condensation vessel connected to said chamber.

The invention further provides apparatus for use in the preparation of fluorocarbon-containing lyophilised
35 contrast agents, which apparatus comprises a lyophilisation or like vacuum chamber adapted to receive one or more containers for lyophilisable precursor

- 20 -

material, means for admitting fluorocarbon gas to said chamber, means for effecting sealing closure of said container(s), means for applying an overpressure of atmospheric gas to said chamber, and a condensation vessel connectable to said chamber and adapted to
5 receive and condense fluorocarbon gas remaining in said chamber after closure of said container(s).

The fluorocarbon gas may be as hereinbefore described, for example a perfluorocarbon such as
10 perfluorobutane, and is desirably introduced into the apparatus through a sterile filter.

The atmospheric gas may be air or a component thereof such as nitrogen, and is preferably sterilised. The use of an overpressure may be advantageous in
15 maintaining closure of the container(s), e.g. to prevent vial stoppers which have been inserted by a moving shelf assembly from sticking to the shelves as these are retracted from the closing position. Shelves in the moving shelf assembly are preferably coated in a non-
20 stick material such as Teflon. The overpressure may also be maintained to assist in flushing residual fluorocarbon gas from the chamber.

The condensation vessel may be the condensation unit of the lyophilisation apparatus, which after
25 lyophilisation may be isolated from the chamber by means of an appropriate valve, heated (e.g. by steam) to melt the ice therein, drained, dried and cooled to a temperature below the boiling point of the fluorocarbon gas. The standard lyophilisation cooling circuit may
30 itself give rise to a temperature within the condensation vessel below the boiling point of the fluorocarbon gas. However, if such a temperature is still above the boiling point further cooling can be achieved using liquid nitrogen or a dry ice/acetone
35 cooling mixture. After introduction of fluorocarbon gas to the chamber, sealing of the container(s) and application of atmospheric gas to the chamber, the

- 21 -

isolating valve may be opened to allow fluorocarbon gas to diffuse to the cooling coil, condense and collect in a solvent tray. The condensed fluorocarbon may be fed to an evacuated flask which is continuously cooled to a temperature below the boiling point of the fluorocarbon and is connected to a drain point in the solvent tray.

Alternatively the feed vessel used to supply the fluorocarbon gas may itself be used as the condensation vessel. Thus the vessel may be isolated from the chamber after introduction of the fluorocarbon gas, cooled (e.g. by immersion in liquid nitrogen) and reconnected to the chamber after sealing of the container(s) and application of atmospheric gas.

As a further alternative an external condenser may be connected to the chamber, e.g. via a throttled vacuum pump. Since fluorinated gases are relatively heavy this should preferably be connected to the bottom of the chamber as far as possible from the atmospheric gas inlet. In one embodiment the condenser may, for example, comprise a vertically positioned cylindrical vessel having a plurality (e.g. three) inlets for fluorocarbon gas spaced around the periphery of its top surface to ensure diffuse entry of gas. The gas descends over a succession of staggered and optionally baffled circumferential cooling coils, condenses and collects at the bottom of the vessel, from where it may be transferred to an evacuated and cooled flask. The flask may be equipped with a cooling coil, preferably having enough turns to maintain the fluorocarbon in liquid form. A concentric axial outlet pipe fitted with drip catchers is positioned within the vessel above the collection zone and passes through the top surface of the vessel into the atmosphere.

In general the recovered condensed fluorocarbon will preferably be subjected to purification (e.g. distillation) and/or sterilisation (e.g. filtration) procedures prior to reuse.

- 22 -

The lyophilisable precursor material may, for example, comprise a dispersion of gas microbubbles in an aqueous medium containing a membrane-forming lipid, e.g. a phospholipid, preferably a negatively charged phospholipid such as a phosphatidylserine.

It has additionally been found that lipid-stabilised gas microbubble-containing contrast agents may be prepared by spray drying procedures which may be simpler and less expensive to operate than the previously described emulsification/lyophilisation procedures and may also lead to efficient formation of substantially monosized microparticles.

Thus according to a further aspect of the invention there is provided a process for the preparation of a contrast agent which comprises lipid-stabilised gas microbubbles wherein a solution or dispersion of said lipid is spray dried in an atmosphere of said gas.

The lipid may, for example, be a phospholipid, preferably a negatively charged phospholipid such as a phosphatidylserine, and may be dissolved or dispersed in an aqueous solvent medium such as water for injection or an aqueous sucrose solution (e.g. such that the end product is isotonic) or an aqueous/organic solvent system such as chloroform/methanol/water, 2-butan-1-ol/water or tetrahydrofuran/water.

Any appropriate gas, e.g. as hereinbefore described, may be employed; the use of fluorinated gases, for example perfluorocarbons such as perfluorobutane, may be particularly advantageous. It will be appreciated that such gases should advantageously be used in a closed system, for example as in pharmaceutical spray drying apparatus manufactured by Niro A/S of Denmark.

Gas-filled hollow microparticles prepared in accordance with such spray drying procedures may be filled directly into vials or like containers ready for reconstitution.

- 23 -

The following non-limitative Examples serve to illustrate the invention.

Brief Description of Drawings

5

In the accompanying drawings:

10

Fig. 1 represents a plot of percentage survival of volume concentration following lyophilisation and reconstitution against relative amount of charged phospholipid in the membranes of contrast agents according to Example 1;

15

Fig. 2 represents plots of attenuation spectra for the frequency range 1.5-8 MHz of contrast agent according to Example 2(a) measured a) before pressure testing, b) during pressure testing, and c) after pressure testing, as described in Example 6;

20

Fig. 3 shows the percentage recovery in attenuation at 3.5 MHz of contrast agent according to Example 2(a) following 90 second applications of overpressures of 0-300 mm Hg as described in Example 6; and

25

Fig. 4 shows volume size distributions for contrast agent according to Example 2(a) measured by Coulter analysis a) without application of overpressure (♦), b) after 90 seconds of overpressure at 150 mm Hg (Δ), and c) after 90 seconds of overpressure at 300 mm Hg (■), as

30

described in Example 6.

- 24 -

Example 1Effects of relative amounts of charged phospholipids

- 5 Dispersions of microbubbles stabilised by different phospholipids or phospholipid mixtures were made according to the general procedure described below, using the process parameters given in Table 1.1 below.
- 10 Solutions of the selected phospholipids or phospholipid mixtures in water containing 5.4% (w/w) of a mixture of propylene glycol and glycerol (3:10 w/w) giving a phospholipid concentration of 2-5 mg/ml were prepared (for phosphatidylethanolamine the water was adjusted to
- 15 pH = 10.5 with sodium hydroxide), the phospholipids being hydrated by ultrasonic treatment and/or heating to approximately 80°C for the stated time (Table 1.1) and cooled to room temperature prior to use. A given volume of this solution was divided between several 2ml
- 20 chromatography vials, using 0.8-1 ml solution per vial. The head space of each vial was filled with perfluorobutane gas, and the vials were securely capped and shaken for 45 seconds using an Espe CapMix® (mixer for dental materials). The resulting microbubble
- 25 dispersions were transferred to a larger vial and centrifuged at 2000 rpm for 5 minutes, giving a turbid infranatant below a floating layer of microbubbles. The infranatant was removed by a syringe and replaced with an equal volume of water at neutral pH. The washing
- 30 step was repeated, but now the infranatant was replaced by 10 % (w/w) sucrose. 2 ml portions of the washed dispersion were divided between 10 ml flat-bottomed vials specially designed for lyophilisation, and the vials were cooled to -47°C and lyophilised for
- 35 approximately 48 hours, giving a white fluffy solid substance. The vials were transferred to a vacuum chamber, and air was removed by a vacuum pump and

- 25 -

replaced by perfluorobutane gas. Prior to use, water was added and the vials were gently hand-shaken for several seconds, giving microbubble dispersions suitable as ultrasound contrast agents.

5

The size distribution and volume concentration of the microbubbles were measured using a Coulter Counter Mark II apparatus fitted with a 50 μm aperture with a measuring range of 1-30 μm . 20 μl samples were diluted in 200 ml saline saturated with air at room temperature and allowed to equilibrate for 3 minutes prior to measurement. The measurements were made on microbubble dispersions prior to lyophilisation (washed bubble dispersion) and after lyophilisation (reconstituted with water to the same volume as before lyophilisation). The data is presented in Table 1.2 below.

The efficiency of lyophilisation for the different phospholipid stabilised microbubble dispersions was calculated as the percentage survival of the volume concentration following lyophilisation and reconstitution. A plot (see Fig. 1 of the drawings) shows how this parameter varies with the relative amount of charged phospholipid in the membrane. As can be seen, the efficiency of lyophilisation increases with increased amount of charged phospholipid in the membrane, being highest for membranes containing charged phospholipids only.

Table 1.1

Composition and process parameters used in production of phospholipid stabilised perfluoro-n-butane gas bubble dispersions as described in Example 1

PLs and ratios (by weight)	Amount PL [mg/ml]	Amount aqueous solvent [ml]	Sonication bath [min]	Heat treatment [min]	Batch size [ml]	Vol. per vial [ml]
DPPE	20	10	-	30	10	0.8
H-PC / H-PS (9:1)	45.5	9.1	10	2	9	0.9
H-PC / H-PS (4:1)	14.0	7	10	2	7	1
DSPC / DSPS (4:1)	10.4	5.2	10	2	4	1
DSPC / DSPG (1:1)	15.2	7.6	10	2	7	1
DPPS	24.9	12.5	-	30	11	1
DSPS	24.8	12.5	-	30	11	1
DSPG / DPPA (10:1)	20.2	10	-	10	10	0.8
DSPG / DPPA (1:1)	52.0	10.4	-	10	8	0.8

Legend:

PL = phospholipid

DPPE = dipalmitoylphosphatidylethanolamine

H-PC = hydrogenated egg phosphatidylcholine

H-PS = hydrogenated egg phosphatidylserine

DSPC = distearoylphosphatidylcholine

DSPS = distearoylphosphatidylserine

DSPG = distearoylphosphatidylglycerol

DPPS = dipalmitoylphosphatidylserine

DPPA = dipalmitoylphosphatidic acid.

- 27 -

Table 1.2

Yield measured as volume concentration of bubbles (in percent of total dispersion volume) (i) after washing the dispersion and (ii) after lyophilisation and reconstitution

PLs and ratios (by weight)	% charged lipid in membrane	Vol. conc. (%) prior to lyophilis- ation	Vol. conc. (%) after lyophilis- ation	Amount surviving lyophilis- ation [% initial vol.conc.]
DPPE	0	0.7	0.1	16.4
H-PC / H-PS (9:1)	10	6.4	0.9	14.1
H-PC / H-PS (4:1)	20	1.0	0.2	20.0
DSPC / DSPS (4:1)	20	4.8	1.0	20.8
DSPC / DSPG (1:1)	50	0.3	0.1	33.3
DPPS	100	0.7	0.4	57.1
DSPS	100	1.0	0.5	50.0
DSPG / DPPA (10:1)	100	1.4	0.7	52.9
DSPG / DPPA (1:1)	100	4.3	1.8	41.9

Legend: See Table 1.1

- 28 -

Example 2a) Preparation of perfluorobutane microbubble dispersions by shaking

5

25.3 mg hydrogenated egg phosphatidylserine was added to 12.5 ml water containing 5.4% (w/w) of a mixture of propylene glycol and glycerol (3:10 w/w). The phospholipid material was hydrated by heating to 70°C for approximately 30 minutes, followed by cooling to room temperature. 11 ml of the dispersion was divided in 1 ml portions between eleven 2 ml vials, and the head space of the vials was filled with perfluoro-n-butane gas. The vials were securely capped and shaken for 45 seconds using an Espe CapMix® (mixer for dental materials). The resulting microbubble dispersions were combined in four larger vials and centrifuged at 2000 rpm for 5 minutes, giving a turbid infranatant below a floating layer of microbubbles. The infranatant was removed by a syringe and replaced with an equal volume of water at neutral pH. The washing step was repeated, but now the infranatant was replaced by 10% (w/w) sucrose. 2 ml portions of the resulting dispersion were divided between 10 ml flat-bottomed vials specially designed for lyophilisation, and the vials were cooled to -47°C and lyophilised for approximately 48 hours, giving a white fluffy solid substance. The vials were transferred to a vacuum chamber, and air was removed by a vacuum pump and replaced by perfluoro-n-butane gas. Prior to use, water was added and the vials were gently hand-shaken for several seconds, giving microbubble dispersions suitable as ultrasound contrast agents.

10

15

20

25

30

- 29 -

b) Preparation of perfluorobutane microbubble dispersions by rotor stator mixing

500.4 mg hydrogenated egg phosphatidylserine was added
5 to 100 ml water containing 5.4% (w/w) of a mixture of
propylene glycol and glycerol (3:10 w/w). The mixture
was shaken and heated to 80°C for five minutes, allowed
to cool to room temperature, shaken again and left
standing overnight prior to use.

10 50 ml of the resulting solution was transferred to a
round-bottomed flask with a conical neck. The flask was
fitted with a glass jacket having a temperature control
inlet and outlet connected to a water bath maintained at
15 25°C. A rotor stator mixing shaft was introduced into
the solution and to avoid gas leakage the space between
the neck wall and the mixing shaft was sealed with a
specially designed metal plug fitted with a gas inlet/
outlet connection for adjustment of gas content and
20 pressure control. The gas outlet was connected to a
vacuum pump and the solution was degassed for one
minute. An atmosphere of perfluoro-n-butane gas was
then applied through the gas inlet.

25 The solution was homogenised at 23000 rpm for 10
minutes, keeping the rotor stator mixing shaft such that
the openings were slightly above the surface of the
liquid. A white coloured creamy dispersion was
obtained, which was transferred to a sealable container
30 and flushed with perfluoro-n-butane. The dispersion was
then transferred to a separating funnel and centrifuged
at 12000 rpm for 30 minutes, yielding a creamy layer of
bubbles at the top and a turbid infranatant. The
infranatant was removed and replaced with water. The
35 centrifugation was then repeated twice, but now at 12000
rpm for 15 minutes. After the last centrifugation, the
supernatant was replaced by 10 % (w/w) sucrose. 2 ml

- 30 -

portions of the resulting dispersion were divided between 10 ml flat-bottomed vials specially designed for lyophilisation, and the vials were cooled to -47°C and lyophilised for approximately 48 hours, giving a white fluffy solid substance. The vials were now transferred to a vacuum chamber, and air was removed by a vacuum pump and replaced by perfluoro-n-butane gas. Prior to use, water was added and the vials were gently hand-shaken for several seconds, giving microbubble dispersions suitable as ultrasound contrast agents.

c) Preparation of perfluorobutane microbubble dispersions by sonication

500.4 mg hydrogenated egg phosphatidylserine was added to 100 ml water containing 5.4% (w/w) of a mixture of propylene glycol and glycerol (3:10 w/w). The mixture was shaken and heated to 80°C for five minutes, allowed to cool to room temperature, shaken again and left standing overnight prior to use.

This solution was pumped through a 4 ml sonicator flow-through cell and exposed to ultrasound at 20 kHz with an amplitude of 90 μ m. The diameter of the sonicator horn was 1.3 cm, the inner diameter of the cell was 2.1 cm and the distance between the horn and the bottom of the cell was 1 cm. The lipid solution was mixed with perfluoro-n-butane at a ratio of 1:2 v/v before it entered the sonicator cell (20 ml/min lipid solution and 40 ml/min perfluoro-n-butane gas). The temperature was kept at 33°C. A white and creamy dispersion was obtained which was filled into a container and flushed with perfluoro-n-butane.

- 31 -

Characterisation

The size distribution and volume concentration of the microbubbles were measured using a Coulter Counter Mark II apparatus fitted with a 50 μm aperture with a measuring range of 1-30 μm . 20 μl samples were diluted in 200 ml saline saturated with air at room temperature, and allowed to equilibrate for 3 minutes prior to measurement.

Ultrasound characterisation was performed on a experimental set up slightly modified from de Jong, N. and Hoff, L. as described in "Ultrasound scattering properties of Albunex microspheres", Ultrasonics 31(3), pp. 175-181 (1993). This instrumentation measures the ultrasound attenuation efficacy in the frequency range 2-8 MHz of a dilute suspension of contrast agent. During the attenuation measurement a pressure stability test was performed by exposing the sample to an overpressure of 120mm Hg for 90 seconds. Typically 2-3 μl of sample was diluted in 55 ml Isoton II and the diluted sample suspension was stirred for 3 minutes prior to analysis. As primary response parameter the attenuation at 3.5 MHz was used, together with the recovery attenuation value at 3.5 MHz after release of the overpressure.

- 32 -

Table 2.1

In vitro characteristics of bubble dispersions produced according to Example 2(a)-(c) (number and volume weighted concentrations and volume mean diameters, as well as acoustic properties measured according to description above)

Production method (Example No.)	Number conc. [10 ⁶ /ml]	Vol. conc. [%]	Vol. mean diam. [μm]	Atten. at 3.5Mhz [dB/cm]	Survival after over-pressure [%]	Freq. at max. atten. [MHz]
2(a)	1519	1.45	3.91	30.46	100	4.1
2(b)	10518	6.51	3.16	150.4	96	4.3
2(c)	23389	9.57	3.83	117	100	3.5

Example 3Effects of gas exchange

The gas contents of five samples prepared according to Example 2(b) above were replaced with air, perfluorobutane, sulphur hexafluoride, trifluoromethylsulphur pentafluoride and tetramethylsilane respectively, according to the following procedure:

Two samples containing lyophilised product from Example 2(b) were placed in a desiccator having a gas inlet and a gas outlet. The desiccator was connected to a Büchi 168 vacuum/distiller controller which permitted controlled evacuation of the samples and inlet of a selected gas. The samples were evacuated at approximately 10 mbar for 5 minutes, whereafter the pressure was increased to atmospheric by inlet of the

- 33 -

selected gas, followed by careful capping of the vials. The procedure was repeated using further pairs of samples for each of the selected gases.

5 2 ml distilled water was added to each vial and the vials were gently hand-shaken prior to use. The resulting microbubble dispersions were characterised with respect to size distribution measurements as described in Example 2. The results are summarised in
10 Table 3.1.

Table 3.1

In vitro characteristics of phosphatidylserine-
15 stabilised microbubble dispersions produced according to
Example 3 - number and volume weighted concentrations
and volume mean diameters

Gas	Number conc. [10 ⁶ /ml]	Number mean diam. [μm]	Vol. conc. [%]	Vol. mean diam. [μm]
20 Perfluorobutane	9756	1.8	4.9	5.8
Trifluoromethyl- sulphur pentafluoride	10243	1.9	5.9	3.5
Sulphur hexafluoride	9927	1.9	5.7	3.2
Tetramethylsilane	9947	1.9	6.1	3.7
25 Air	9909	1.9	6.4	4.0

As will be seen from the above results there was no
significant change in size distribution upon gas
30 exchange.

- 34 -

In vivo results

One batch prepared with each of the five gases was evaluated *in vivo* for Doppler enhancement properties at 10 MHz. The dispersions were injected into chinchilla rabbits via an ear vein and measured using a Doppler technique where an ultrasound probe was placed directly on a carotid artery. Signal intensities and duration were recorded and the integral of the Doppler curve was calculated. The results obtained (see Table 3.2 below) showed that microbubbles containing perfluorobutane gave the strongest Doppler intensity enhancement. Microbubbles containing sulphur hexafluoride, trifluoromethylsulphur pentafluoride or tetramethylsilane were only slightly less efficacious as Doppler enhancers than those containing perfluorobutane, giving integrals in the range 60-80% of the figure for perfluorobutane.

20 Table 3.2

Results for i.v. injections of Example 3 products into rabbits (values are adjusted for drift in baseline; the Doppler unit is defined as the increase in Doppler signal relative to that of blood)

Gas	Integrated Arterial Doppler Enhancement (NDU.s)
Perfluorobutane*	10361
Trifluoromethylsulphur pentafluoride	8006
Tetramethylsilane	6370
Sulphur hexafluoride	6297
Air	1024

35 * Average of two injections

- 35 -

Example 4Frozen dispersions and lyophilised products

5 250 mg hydrogenated egg phosphatidylserine was added to
50 ml water for injection containing 5.4% (w/w) of a
mixture of propylene glycol and glycerol (7:20 w/w).
The mixture was shaken and heated to 80°C for five
minutes, allowed to cool to room temperature, shaken
10 again and left standing overnight prior to use.

100 ml of the resulting solution was transferred to a
round-bottomed flask with a conical neck and processed
according to the procedure described in Example 2(b). A
15 white coloured creamy dispersion was formed. This
dispersion was transferred to a separating funnel and
centrifuged at 12000 rpm for 30 minutes, yielding a
creamy layer of microbubbles at the top and a turbid
infranatant. The infranatant was removed and replaced
20 with 50 ml water for injection. The centrifugation was
then repeated twice, but now at 12000 rpm for 15
minutes. To 6 ml of the resulting dispersion was added
6 ml 30 % (w/w) trehalose; 2 ml portions of this
dispersion were divided between 10 ml flat-bottomed
25 vials specially designed for lyophilisation, and the
vials were cooled to -47°C and stored at this
temperature for one day.

Half of the vials were thawed after one day at -47°C,
30 giving homogeneous creamy white dispersions of gas
microbubbles suitable as ultrasound contrast agents.
The thawed dispersions were characterised by measuring
size distribution as described in Example 2 above (see
Table 4.1). The remaining vials were lyophilised for
35 approximately 48 hours, giving a white fluffy solid
substance. The vials were transferred to a vacuum
chamber, and air was removed by a vacuum pump and

- 36 -

replaced by perfluoro-n-butane gas. Prior to use, water was added and the vials were gently hand-shaken for several seconds, giving bubble dispersions suitable as ultrasound contrast agents. The reconstituted products were characterised by measuring size distribution and acoustic attenuation using the methods as described in Example 2 above. The results are presented in Table 4.1.

Table 4.1

Bubble concentration, size data and acoustic data of perfluoro-n-butane gas bubble dispersions stabilised by hydrogenated phosphatidylserine, treated by freeze - thawing and lyophilisation

Sample treatment	Number conc. [10 ⁶ /ml]	Vol. conc. [%]	Vol. mean diam. [μm]	Atten. at 3.5Mhz [dB/cm]	Survival after over-pressure [%]	Freq. at max. atten. [MHz]
Washed	10390	10.4	3.8	n.a.	n.a.	n.a.
Freeze-thawed	10142	9.9	3.6	n.a.	n.a.	n.a.
Lyophilised	7780	4.6	3.1	58.0	89	5.3

Legend:

n.a. = not analysed

Example 5

Exposure of perfluorobutane microbubble dispersion to air-saturated fluid

A vial containing lyophilised material under an atmosphere of perfluorobutane was prepared as described in Example 2(b). Water was added to the vial just

- 37 -

before use to give a microbubble dispersion.

200 ml Isoton II fluid was exposed to air for several days at room temperature to give a fully air-saturated solution. Another 200 ml of the fluid was degassed in a vacuum flask at 60°C for one hour and cooled to room temperature while maintaining the vacuum. Air was admitted to the flask immediately prior to use.

10 10 μ l portions of the microbubble suspension were added to each of the fluids and the resulting mixtures were incubated for 5 minutes prior to size characterisation (Coulter Multisizer Mark II).

15 In the degassed environment, where no diffusion of gases from the fluid into the microbubbles would be expected, the mean microbubble diameter was 1.77 μ m and 0.25% of the microbubbles were larger than 5 μ m. In the air-saturated fluid the corresponding values were 2.43 μ m and 0.67%; repeated measurements made after a further 5 minutes indicated that the microbubble sizes had reached a stable value.

25 These findings show that the average diameter of the microbubbles increased by only 37% when they were exposed to an air-saturated fluid analogous to arterial blood, with very few microbubbles reaching a size which might cause blockage of capillary blood vessels. This may be contrasted with the doubling in size of air/perfluorohexane-containing microbubbles in a similar environment (i.e. a highly diluted dispersion of microbubbles in water containing dissolved air) reported in Example II of WO-A-9503835.

- 38 -

Example 6Pressure stability of perfluorobutane microbubble dispersion

5

Vials containing lyophilised material under an atmosphere of perfluorobutane were prepared as described in Example 2(a). Water (2 ml) was added to the vials just before use to give microbubble dispersions.

10

Attenuation spectra were recorded for 1.5-8 MHz before, during and after application of an overpressure of air at 300 mm Hg; the pressure was released after 90 seconds. The results are shown in Fig. 2 of the drawings, and indicate that although attenuation at 4 MHz (the peak for unpressurised contrast agent) fell to less than one third under pressure, it was almost fully (85%-95%) restored when the pressure was released.

15

20

Overpressures of air at up to 300 mm Hg were applied for 90 seconds duration and attenuation was measured at 3.5 MHz. The results are shown in Fig. 3 of the drawings and indicate good recovery of attenuation (at least about 95%) following pressure release for all the overpressures used.

25

30

Size distributions were determined by Coulter analysis for a non-pressurised sample and for samples subjected to overpressures of air at 150 and 300 mm Hg applied for durations of 90 seconds. The results are shown in Fig. 4 of the drawings and indicate that there were no significant differences between the distribution curves in the range 1-10 μm .

- 39 -

Example 7Preparation of perfluorobutane microbubble dispersion by spray drying

5

Microbubbles are produced by spray drying a phospholipid dispersion comprising 1 mg/ml hydrogenated phosphatidylserine in a chloroform/methanol/water (100:20:0.1 v/v) mixture in a perfluorobutane

10

atmosphere. After reconstitution with water the product shows echogenic properties.

- 40 -

Claims

1. A process for the preparation of a fluorocarbon-containing lyophilised contrast agent which comprises
5 lyophilising lyophilisable precursor material contained in one or more containers in a lyophilisation or like vacuum chamber, introducing said fluorinated gas into said chamber and effecting sealing closure of said container or containers, characterised in that,
10 following closure of said container or containers, an overpressure of an atmospheric gas is applied to said chamber and said fluorocarbon gas is allowed to condense in a condensation vessel connected to said chamber.
- 15 2. A process as claimed in claim 1 wherein said fluorocarbon gas is a perfluorinated low molecular weight hydrocarbon.
- 20 3. A process as claimed in claim 2 wherein said fluorocarbon gas is perfluorobutane.
4. A process as claimed in any one of claims 1 to 3 wherein said atmospheric gas is air.
- 25 5. A process as claimed in any one of claims 1 to 4 wherein said atmospheric gas is sterilised.
6. A process as claimed in any one of claims 1 to 5 wherein said lyophilisable precursor material comprises
30 a dispersion of gas microbubbles in an aqueous medium containing a membrane-forming lipid.
7. A process as claimed in claim 6 wherein said lipid comprises at least one phospholipid.
- 35 8. A process as claimed in claim 7 wherein said phospholipid predominantly comprises molecules which

- 41 -

individually bear a net overall negative charge.

9. A process as claimed in claim 8 wherein at least
70% of said phospholipid comprises one or more
5 phosphatidylserines.

10. A process as claimed in any one of claims 1 to 9
wherein said fluorocarbon is introduced into said
chamber through a sterile filter.

10
11. Apparatus for use in the preparation of
fluorocarbon-containing lyophilised contrast agents,
which apparatus comprises a lyophilisation or like
vacuum chamber adapted to receive one or more containers
15 for lyophilisable precursor material, means for
admitting fluorocarbon gas to said chamber, means for
effecting sealing closure of said container(s), means
for applying an overpressure of atmospheric gas to said
chamber, and a condensation vessel connectable to said
20 chamber and adapted to receive and condense fluorocarbon
gas remaining in said chamber after closure of said
container(s).

25 12. An apparatus as claimed in claim 11 wherein said
means for effecting sealing closure of said container(s)
comprises a moving shelf assembly adapted to insert
stoppers into said containers.

30 13. An apparatus as claimed in claim 12 wherein said
shelves are coated with a non-stick material.

14. A process for the preparation of a contrast agent
which comprises lipid-stabilised gas microbubbles
wherein a solution or dispersion of said lipid is spray
35 dried in an atmosphere of said gas.

1/3

Percent survival after lyophilization




FIG. 1




FIG. 2

2/3




FIG. 3

3/3




FIG. 4